Kimura Y, Okuda H, Arichi S
Second Department of Medical Biochemistry, School of Medicine, Ehime University, Japan.
J Pharm Pharmacol. 1988 Dec;40(12):838-43. doi: 10.1111/j.2042-7158.1988.tb06285.x.
The effects of various ginseng saponins isolated from red ginseng roots, on aggregation and 5-hydroxytryptamine release (5-HT) human platelets have been investigated. Among the six saponins tested, only ginsenoside Rg1 inhibited adrenaline- and thrombin-induced platelet aggregation and 5-HT release dose-dependently, at concentrations of 5 to 500 micrograms ML-1. Ginsenoside Rg1 had no effect on adrenaline- and thrombin-induced arachidonic acid release and diacylglycerol production. But it did reduce the elevation of cytosolic free calcium concentration (Ca2+)i shown in the second phase induced by adrenaline and thrombin, at concentrations of 10 to 500 micrograms mL-1. Those data suggest that the inhibitory effects of ginsenoside Rg1 on 5-HT release from, and aggregation of, platelets might be due to the reduction of (Ca2+)i elevation at the second phase induced by adrenaline and thrombin. The results suggest that ginsenoside Rg1 in red ginseng roots may be active as a drug in the treatment of artheroscleorosis and thrombosis.
对从红参根中分离出的各种人参皂苷对人血小板聚集及5-羟色胺释放（5-HT）的影响进行了研究。在所测试的六种皂苷中，只有人参皂苷Rg1在浓度为5至500微克/毫升时，能剂量依赖性地抑制肾上腺素和凝血酶诱导的血小板聚集及5-HT释放。人参皂苷Rg1对肾上腺素和凝血酶诱导的花生四烯酸释放及二酰基甘油生成没有影响。但在浓度为10至500微克/毫升时，它确实能降低肾上腺素和凝血酶诱导的第二阶段所显示的胞质游离钙浓度（Ca2+）i的升高。这些数据表明，人参皂苷Rg1对血小板5-HT释放及聚集的抑制作用可能是由于降低了肾上腺素和凝血酶诱导的第二阶段（Ca2+）i的升高。结果表明，红参根中的人参皂苷Rg1可能作为一种药物在动脉粥样硬化和血栓形成的治疗中具有活性。
